Dyne Delivers In Duchenne Trial; Now Aims To ACHIEVE Myotonic Dystrophy Milestones

Dyne Therapeutics reported positive Phase 1/2 DELIVER Registrational Expansion Cohort data for Zeleciment rostudirsen (DYNE-251) in exon 51–amenable Duchenne muscular dystrophy, showing a statistically significant rise in dystrophin to 5.46% at six months, functional improvements across endpoints, preserved lung function and sustained benefits with a favorable safety profile through 24 months. The company plans a BLA filing for U.S. Accelerated Approval in Q2 2026 and to initiate a global Phase 3 program concurrently, targeting potential U.S. availability in Q1 2027 assuming Priority Review. Dyne’s second program, Zeleciment basivarsen (DYNE-101) for myotonic dystrophy type 1, is advancing its ACHIEVE registrational expansion cohort with enrollment due to finish in early Q2 2026 and a potential BLA in early Q3 2027 if outcomes support approval. The firm ended September 30, 2025 with $791.9 million in cash and equivalents, has launched a $300 million equity offering to bolster its balance sheet and pipeline, and its stock has risen notably year-to-date to $22.20.

Analysis

Dyne Therapeutics announced registrational expansion cohort results from the Phase 1/2 DELIVER trial for Zeleciment rostudirsen (DYNE-251) showing a statistically significant increase in dystrophin to 5.46% at six months, functional improvements across multiple clinical endpoints, maintained lung function, and a favorable safety/tolerability profile sustained through 24 months. The company plans a U.S. Accelerated Approval BLA submission in Q2 2026 and intends to initiate a global Phase 3 program in the same period, targeting potential commercial availability in Q1 2027 assuming FDA grants Priority Review. Dyne also highlighted progress on a second program, Zeleciment basivarsen (DYNE-101) in Myotonic Dystrophy Type 1 with ACHIEVE REC enrollment expected to finish in early Q2 2026 and a potential BLA in early Q3 2027, indicating a multi-program development runway. The balance sheet shows $791.9 million in cash and equivalents as of Sept. 30, 2025, but management commenced a $300 million underwritten equity offering yesterday, and the stock has risen from about $9.50 in July to $22.20 yesterday (up 9.47%), reflecting market optimism but also potential near-term dilution and binary regulatory execution risk.

Key Decisions for Investors

• Consider adding or maintaining a tactical exposure to DYN ahead of the Q2 2026 BLA submission given positive DELIVER data, but size positions for binary regulatory risk
• Monitor key near-term catalysts closely: BLA submission timing in Q2 2026, initiation of global Phase 3, ACHIEVE REC enrollment completion in early Q2 2026, and any FDA communications on Priority Review
• Account for dilution risk from the $300 million equity offering when modeling share count and late-2026/early-2027 commercialization economics
• Use position sizing or hedges (e.g., protective puts or collars) to manage downside ahead of regulatory decisions and Phase 3 readouts